Mythic Therapeutics

Mythic Therapeutics is a biotechnology startup that operates in the healthcare sector, specifically in the field of cancer treatment. The company's primary focus is on the development and commercialization of antibody-drug conjugates (ADCs), a type of targeted chemotherapy. ADCs are designed to deliver chemotherapy directly to cancer cells, thereby reducing the impact on healthy tissues. However, the current challenge with ADCs is that more than 95% of the dose often ends up in healthy tissues, which decreases the drug's effectiveness and increases toxicity.

Mythic's innovative solution to this problem is their proprietary technology, FateControl™. This technology increases the uptake of ADCs in cancer cells while preventing payload release in normal cells. The result is a significant increase in the effectiveness of the treatment for a wide range of cancer types, without causing unacceptable side effects or toxicity. This could potentially lead to better treatment outcomes for a broader patient population.

Mythic Therapeutics operates on a business model that involves the development of this technology and its application in creating more effective cancer treatments. The company generates revenue through the commercialization of its technology and the development of new treatments.

The team at Mythic is composed of experienced entrepreneurs and innovators, who are dedicated to improving patient outcomes through their work. They are committed to changing the state of the art in cancer treatment, bringing us closer to realizing the full potential of ADCs for patients across the world.

Keywords: Biotechnology, Healthcare, Cancer Treatment, Antibody-Drug Conjugates (ADCs), FateControl™ Technology, Targeted Chemotherapy, Patient Outcomes, Entrepreneurs, Innovators, Commercialization.